EP2961409 - INHIBITORS OF CDK8/19 FOR USE IN TREATING ESTROGEN RECEPTOR POSITIVE BREAST CANCER [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 27.01.2017 Database last updated on 31.08.2024 | Most recent event Tooltip | 27.01.2017 | Application deemed to be withdrawn | published on 01.03.2017 [2017/09] | Applicant(s) | For all designated states Senex Biotechnology, Inc. 715 Sumpter Street Coker Life Science Building Room 513 Columbia, SC 29208 / US | [2016/01] | Inventor(s) | 01 /
BROUDE, Eugenia 225 Porth Circle Lexington, SC 29072 / US | 02 /
RONINSON, Igor, B 225 Porth Circle Lexington, SC 29072 / US | [2016/01] | Representative(s) | Hiebl, Inge Elisabeth Kraus & Weisert Patentanwälte PartGmbB Thomas-Wimmer-Ring 15 80539 München / DE | [2016/01] | Application number, filing date | 14713958.8 | 26.02.2014 | [2016/01] | WO2014US18678 | Priority number, date | US201361769435P | 26.02.2013 Original published format: US 201361769435 P | [2016/01] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2014134169 | Date: | 04.09.2014 | Language: | EN | [2014/36] | Type: | A1 Application with search report | No.: | EP2961409 | Date: | 06.01.2016 | Language: | EN | The application published by WIPO in one of the EPO official languages on 04.09.2014 takes the place of the publication of the European patent application. | [2016/01] | Search report(s) | International search report - published on: | EP | 04.09.2014 | Classification | IPC: | A61K31/517, A61K31/00, A61K45/06, A61P35/00 | [2016/01] | CPC: |
A61K31/517 (EP,US);
A61K31/00 (EP,US);
A61K31/5377 (EP,US);
A61K31/565 (EP,US);
A61K45/06 (EP,US);
A61P35/00 (EP)
| C-Set: |
A61K31/517, A61K2300/00 (EP,US)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2016/01] | Title | German: | INHIBITOREN VON CDK8/19 ZUR VERWENDUNG BEI DER BEHANDLUNG VON ÖSTROGENREZEPTORPOSITIVEM BRUSTKREBS | [2016/01] | English: | INHIBITORS OF CDK8/19 FOR USE IN TREATING ESTROGEN RECEPTOR POSITIVE BREAST CANCER | [2016/01] | French: | INHIBITEURS DE CDK8/19 POUR UTILISATION DANS LE TRAITEMENT DU CANCER DU SEIN À RÉCEPTEURS D' STROGÈNE POSITIFS | [2016/01] | Entry into regional phase | 25.09.2015 | National basic fee paid | 25.09.2015 | Designation fee(s) paid | 25.09.2015 | Examination fee paid | Examination procedure | 25.09.2015 | Examination requested [2016/01] | 01.09.2016 | Application deemed to be withdrawn, date of legal effect [2017/09] | 06.10.2016 | Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time [2017/09] | Fees paid | Penalty fee | Additional fee for renewal fee | 29.02.2016 | 03   M06   Not yet paid |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [I]US2010069383 (ANDERSON MARK B [US], et al) [I] 1,10-15 * page 6, paragraphs [0057]-[0060] * * page 58, paragraph [1346] * * page 59, paragraph [1351] * * examples 26, 177, 179, 262, 265 *; | [I]WO2011011522 (HARVARD COLLEGE [US], et al) [I] 1,10-15 * page 42, lines 27-29 * * page 43, line 23 - page 44, line 4 * * claims 39, 41-43, 51, 53-56 * * figure 14 *; | [A]US2012071477 (PORTER DONALD C [US], et al) [A] 1-18 * figures 1, 2, 6, 7 * * page 3, paragraph [0027] * * page 4, paragraphs [0045]-[0048] * * page 5, paragraph [0051] * * page 6, paragraph [0055] * * page 7, paragraph [0065] * * pages 7-8, paragraph [0070] * * examples 4, 7 *; | [IP]WO2013116786 (SENEX BIOTECHNOLOGY INC [US]) [IP] 1-18 * page 3, paragraphs 2, 4 * * page 5, paragraph 3 * * page 6, paragraph 9 * * page 7, paragraphs 2-3 * * page 8, paragraph 4 - page 9, paragraph 1 * * page 13, paragraph 6 * * examples 9, 11-14 * * claims 1-30 *; | [ID] - D. C. PORTER ET AL, "Cyclin-dependent kinase 8 mediates chemotherapy-induced tumor-promoting paracrine activities", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, (20120821), vol. 109, no. 34, doi:10.1073/pnas.1206906109, ISSN 0027-8424, pages 13799 - 13804, XP055056523 [ID] 1-18 * abstract * * page 13799, column 2, paragraph 2 * * page 13800, column 1, paragraph 1 * * figure 1 * * page 13802, column 2, paragraph 5 - page 13803, column 2, paragraph 1 * * figure 4 * * page 13804, column 1, paragraph l - column 2, paragraph 1 * DOI: http://dx.doi.org/10.1073/pnas.1206906109 | [I] - Steven Powell, "A new approach to improving cancer chemotherapy", University of South Carolina - News, (20120806), page 1, URL: http://www.sc.edu/news/newsarticle.php?nid=4315#.U3nIglPsx8E, (20140519), XP055118617 [I] 1-18 * page 1, paragraphs 2, 9-10 * | [I] - ALAFEEFY AHMED M ET AL, "Design, synthesis and biological evaluation of novel quinazoline derivatives as potential anti-cancer agents", JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, TAYLOR, READING, GB, (20120801), vol. 27, no. 4, doi:10.3109/14756366.2011.601302, ISSN 1475-6366, pages 541 - 545, XP008169336 [I] 1,10-15 * abstract * * figure scheme 1; compounds 4, 5, 12-15 * * page 543, column 2, paragraph 1 * DOI: http://dx.doi.org/10.3109/14756366.2011.601302 | [I] - ESTHER MORENO ET AL, "Sulfur and selenium derivatives of quinazoline and pyrido[2,3-]pyrimidine: Synthesis and study of their potential cytotoxic activity", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 47, doi:10.1016/J.EJMECH.2011.10.056, ISSN 0223-5234, (20111028), pages 283 - 298, (20111106), XP028442406 [I] 1,10-15 * abstract * * figure 2 * * figure scheme 1; compounds 2e-2j, 2l-2o * * figure scheme 3; compounds 7a-7i * * page 287, column 2, paragraph 3 * * table 1 * DOI: http://dx.doi.org/10.1016/j.ejmech.2011.10.056 | [A] - MCDONNELL D P ET AL, "The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer", CURRENT OPINION IN PHARMACOLOGY, ELSEVIER SCIENCE PUBLISHERS, NL, vol. 10, no. 6, doi:10.1016/J.COPH.2010.09.007, ISSN 1471-4892, (20101201), pages 620 - 628, (20101111), XP027491049 [A] 5-9 * abstract * * page 625, column 2, paragraph 2 * DOI: http://dx.doi.org/10.1016/j.coph.2010.09.007 | [XPI] - LI XIAO-YU ET AL, "siRNA-mediated silencing of CDK8 inhibits proliferation and growth in breastcancer cells", vol. 7, no. 1, ISSN 1936-2625, (20140101), pages 92 - 100, INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, E-CENTURY PUBLISHING CORPORATION, US, URL: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3885463/, (20131215), XP008169367 [XP] 1 * abstract * * page 93, column 1, paragraphs 2, 5 * * figures 2-4 * * page 96, column 1, paragraph 1 - column 2, paragraph 1 * * page 98, column 1, paragraph 1 * * page 98, column 2, paragraph 2 - page 99, column 1, paragraph 2 * [I] 2-18 | by applicant | - BELAKAVADI,M.; FONDELL,J.D., "Cyclin-dependent kinase 8 positively cooperates with Mediator to promote thyroid hormone receptor-dependent transcriptional activation", MOL. CELL BIOL., (2010), vol. 30, pages 2437 - 2448 | - CATANIA,C.; ASCIONE,G.; ADAMOLI,L.; DE,P.T.; MEDICI,M.; FRANCESCHELLI,L.; VERRI,E.; MAGNI,E.; SANNA,G.; TORRISI,R., "Fulvestrant in heavily pre-treated patients with advanced breast cancer: results from a single compassionate use programme centre", BREAST CANCER RES. TREAT., (2007), vol. 106, doi:doi:10.1007/s10549-006-9481-8, pages 97 - 103, XP019524467 DOI: http://dx.doi.org/10.1007/s10549-006-9481-8 | - FIRESTEIN,R.; BASS,A.J.; KIM,S.Y.; DUNN,I.F.; SILVER,S.J.; GUNEY,I.; FREED,E.; LIGON,A.H.; VENA,N.; OGINO,S., "CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity", NATURE, (2008), vol. 455, doi:doi:10.1038/nature07179, pages 547 - 551, XP055124701 DOI: http://dx.doi.org/10.1038/nature07179 | - FIRESTEIN,R.; HAHN,W.C., "Revving the Throttle on an oncogene: CDK8 takes the driver seat", CANCER RES, (2009), vol. 69, pages 7899 - 7901 | - FIRESTEIN,R.; SHIMA,K.; NOSHO,K.; IRAHARA,N.; BABA,Y.; BOJARSKI,E.; GIOVANNUCCI,E.L.; HAHN,W.C.; FUCHS,C.S.; OGINO,S., "CDK8 expression in 470 colorectal cancers in relation to beta-catenin activation, other molecular alterations and patient survival", INT. J. CANCER, (2010), vol. 126, pages 2863 - 2873 | - GALBRAITH,M.D.; DONNER,A.J.; ESPINOSA,J.M., "CDK8: a positive regulator of transcription", TRANSCRIPTION, (2010), vol. 1, pages 4 - 12 | - KAPOOR,A.; GOLDBERG,M.S.; CUMBERLAND,L.K.; RATNAKUMAR,K.; SEGURA,M.F.; EMANUEL,P.O.; MENENDEZ,S.; VARDABASSO,C.; LEROY,G.; VIDAL,C, "The histone variant macroH2A suppresses melanoma progression through regulation ofCDK8", NATURE, (2010), vol. 468, pages 1105 - 1109 | - MCDONNELL,D.P.; WARDELL,S.E., "The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer", CURR. OPIN. PHARMACOL., (2010), vol. 10, doi:doi:10.1016/j.coph.2010.09.007, pages 620 - 628, XP027491049 DOI: http://dx.doi.org/10.1016/j.coph.2010.09.007 | - MULLER,A.; HOMEY,B.; SOTO,H.; GE,N.; CATRON,D.; BUCHANAN,M.E.; MCCLANAHAN,T.; MURPHY,E.; YUAN,W.; WAGNER,S.N., "Involvement of chemokine receptors in breast cancer metastasis", NATURE, (2001), vol. 410, doi:doi:10.1038/35065016, pages 50 - 56, XP002292390 DOI: http://dx.doi.org/10.1038/35065016 | - PORTER,D.C.; FARMAKI,E.; ALTILIA,S.; SCHOOLS,G.P.; WEST,D.K.; CHEN,M.; CHANG,B.D.; PUZYREV,A.T.; LIM,C.U.; ROKOW-KITTELL,R., "Cyclin-dependent kinase 8 mediates chemotherapy-induced tumor- promoting paracrine activities", PROC. NATL. ACAD. SCI. U. S. A, (2012), vol. 109, doi:doi:10.1073/pnas.1206906109, pages 13799 - 13804, XP055056523 DOI: http://dx.doi.org/10.1073/pnas.1206906109 | - RAE,J.M.; JOHNSON,M.D.; SCHEYS,J.O.; CORDERO,K.E.; LARIOS,J.M.; LIPPMAN,M.E., "GREB 1 is a critical regulator of hormone dependent breast cancer growth", BREAST CANCER RES. TREAT., (2005), vol. 92, pages 141 - 149, XP019274841 | - RHODES,L.V.; SHORT,S.P.; NEEL,N.F.; SALVO,V.A.; ZHU,Y.; ELLIOTT,S.; WEI,Y.; YU,D.; SUN,M.; MUIR,S.E., "Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer", CANCER RES., (2011), vol. 71, pages 603 - 613 | - SAUVE,K.; LEPAGE,J.; SANCHEZ,M.; HEVEKER,N.; TREMBLAY,A., "Positive feedback activation of estrogen receptors by the CXCL12-CXCR4 pathway", CANCER RES., (2009), vol. 69, pages 5793 - 5800 | - SIKORA,M.J.; STRUMBA,V.; LIPPMAN,M.E.; JOHNSON,M.D.; RAE,J.M., "Mechanisms of estrogen-independent breast cancer growth driven by low estrogen concentrations are unique versus complete estrogen deprivation", BREAST CANCER RES. TREAT., (2012), vol. 134, doi:doi:10.1007/s10549-012-2032-6, pages 1027 - 1039, XP035093059 DOI: http://dx.doi.org/10.1007/s10549-012-2032-6 | - SWEENEY,E.E.; MCDANIEL,R.E.; MAXIMOV,P.Y.; FAN,P.; JORDAN,V.C., "Models and Mechanisms of Acquired Antihormone Resistance in Breast Cancer: Significant Clinical Progress Despite Limitations", HORM. MOL. BIOL. CLIN. INVESTIG., (2012), vol. 9, pages 143 - 163 | - WANG YC; MORRISON G; GILLIHAN R; GUO J; WARD RM; FU X; BOTERO MF; HEALY NA; HILSENBECK SG; PHILLIPS GL, "Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation", BREAST CANCER RESEARCH, (2011), vol. 13, doi:doi:10.1186/bcr3067, page R121, XP021119741 DOI: http://dx.doi.org/10.1186/bcr3067 | - WESTERLING,T.; KUULUVAINEN,E.; MAKELA,T.P., "Cdk8 is essential for preimplantation mouse development", MOL. CELL BIOL., (2007), vol. 27, pages 6177 - 6182 | - WILSON,T.R.; FRIDLYAND,J.; YAN,Y.; PENUEL,E.; BURTON,L.; CHAN,E.; PENG,J.; LIN,E.; WANG,Y.; SOSMAN,J., "Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors", NATURE, (2012), vol. 487, pages 505 - 509 | - XU,W.; JI,J.Y., "Dysregulation of CDK8 and Cyclin C in tumorigenesis", J. GENET. GENOMICS, (2011), vol. 38, doi:doi:10.1016/j.jgg.2011.09.002, pages 439 - 452, XP028327936 DOI: http://dx.doi.org/10.1016/j.jgg.2011.09.002 |